Anzeige
Mehr »
Montag, 30.03.2026 - Börsentäglich über 12.000 News
Strategischer Rohstoff-Hebel: Chinas Export-Stopp schockt den Westen - Ist diese Aktie die Antwort auf den Notstand?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJCN | ISIN: KYG970081173 | Ticker-Symbol: 1FW2
Tradegate
27.03.26 | 13:55
3,561 Euro
+2,09 % +0,073
Branche
Pharma
Aktienmarkt
HANG SENG
1-Jahres-Chart
WUXI BIOLOGICS CAYMAN INC Chart 1 Jahr
5-Tage-Chart
WUXI BIOLOGICS CAYMAN INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,5223,56629.03.
3,5003,59327.03.

Aktuelle News zur WUXI BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCMBI Raises TP of WUXI BIO to HKD39, Maintains 'Buy' Rating4
DoUBS Lowers EPS Forecasts for WUXI BIO for This and Next Year, Slightly Reduces TP to HKD49.37
WUXI BIOLOGICS Aktie jetzt für 0€ handeln
MiWUXI BIO (02269): GRANT OF RESTRICTED SHARES UNDER RESTRICTED SHARE AWARD SCHEME6
DiWuXi Bio's record number of new projects in 2025 leaned heavily on US clients8
DiWuXi Biologics Reports Record 2025 Annual Results459Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps...
► Artikel lesen
DiWuxi Biologics ADR Non-GAAP EPS of ¥1.33, revenue of ¥21.79M3
DiWUXI BIO (02269): INSIDE INFORMATION - 2025 ANNUAL RESULTS PRESENTATION7
DiWUXI BIO Annual NP RMB4.908B, Up 46.3%; Adj. NP Up 17.9%3
DiWUXI BIO (02269): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 202510
16.02.BRIEF: CANbridge raises $26 million in share sale to WuXi Bio at 14.7% discount14
11.02.WUXI BIO (02269): DATE OF BOARD MEETING14
11.02.WUXI BIO (02269): POSITIVE PROFIT ALERT7
03.02.WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease668CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and...
► Artikel lesen
03.02.WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager13
29.01.WuXi Biologics, Sinorda Biomedicine Partner to Advance SND0064
29.01.WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody237SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today...
► Artikel lesen
26.01.HanchorBio and WuXi Biologics partner on fusion protein development6
26.01.HanchorBio und WuXi Biologics schließen strategische Partnerschaft zur Entwicklung von Fusionsproteinen10
26.01.HanchorBio Inc.: HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline162SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies...
► Artikel lesen
16.01.WUXI BIO (02269): INSIDE INFORMATION - PLACING OF EXISTING SHARES BY SUBSTANTIAL SHAREHOLDER3
Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1